AAM
IART icon

Azzad Asset Management’s Integra LifeSciences IART Stock Holding History

Azzad Asset Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-10,807
Closed -$444K – 315
2023
Q2 		$444K Buy
10,807
+239
+2% +$11.5K 0.06% 285
2023
Q1 		$607K Buy
10,568
+201
+2% +$11.3K 0.09% 259
2022
Q4 		$581K Sell
10,367
-21,749
-68% -$1.11M 0.09% 248
2022
Q3 		$1.46M Sell
32,116
-45
-0.1% -$2.31K 0.15% 205
2022
Q2 		$1.58M Buy
32,161
+21,966
+215% +$1.32M 0.16% 194
2022
Q1 		$655K Sell
10,195
-6,438
-39% -$424K 0.09% 253
2021
Q4 		$1.11M Buy
+16,633
New +$1.13M 0.15% 225
2020
Q3 		– Sell
-21,798
Closed -$1.02M – 303
2020
Q2 		$1.02M Buy
21,798
+5,856
+37% +$288K 0.24% 155
2020
Q1 		$712K Sell
15,942
-21,349
-57% -$1.12M 0.21% 172
2019
Q4 		$1.93M Buy
37,291
+61
+0.2% +$3.63K 0.23% 158
2019
Q3 		$1.95M Buy
37,230
+20,582
+124% +$1.23M 0.24% 151
2019
Q2 		$930K Buy
16,648
+4,378
+36% +$225K 0.26% 155
2019
Q1 		$684K Buy
12,270
+1,250
+11% +$63.7K 0.2% 185
2018
Q4 		$497K Sell
11,020
-1,336
-11% -$73.3K 0.17% 211
2018
Q3 		$814K Sell
12,356
-940
-7% -$58.4K 0.22% 175
2018
Q2 		$856K Buy
13,296
+150
+1% +$9.29K 0.25% 158
2018
Q1 		$728K Buy
13,146
+372
+3% +$19.5K 0.22% 173
2017
Q4 		$611K Sell
12,774
-1,631
-11% -$79.8K 0.19% 175
2017
Q3 		$727K Buy
14,405
+819
+6% +$42.1K 0.24% 151
2017
Q2 		$741K Sell
13,586
-604
-4% -$28.8K 0.27% 140
2017
Q1 		$598K Buy
14,190
+2,088
+17% +$89.2K 0.23% 174
2016
Q4 		$519K Buy
12,102
+444
+4% +$18K 0.21% 172
2016
Q3 		$481K Buy
+11,658
New +$488K 0.2% 177
2015
Q4 		– Sell
-9,900
Closed -$295K – 246
2015
Q3 		$295K Buy
9,900
+2,353
+31% +$73.6K 0.16% 211
2015
Q2 		$208K Buy
+7,547
New +$201K 0.1% 243

Other funds holding IART

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
CB
Cooke & Bieler Philadelphia, Pennsylvania $8.84B AUM 6.92% 1-Year Est. Return
CIP
Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Azzad Asset Management's IART Position: Q3 2023 in Review

Azzad Asset Management sold out of Integra LifeSciences (IART) in Q3 2023, closing a stake of 10,807 shares — an estimated $444K sold.

Azzad Asset Management first reported a position in IART in Q2 2015 and held it in 25 quarters. The position peaked at $1.95M in Q3 2019. 262 funds tracked by Wall St. Rank hold IART as of Q3 2023.

  • Azzad Asset Management reported no remaining Integra LifeSciences position as of Q3 2023 after selling out during the quarter.
  • Azzad Asset Management sold 10,807 Integra LifeSciences shares in Q3 2023, an estimated $444K.
  • Azzad Asset Management first reported a position in Integra LifeSciences in Q2 2015 and held it in 25 quarters.
  • Azzad Asset Management's Integra LifeSciences position peaked at $1.95M in Q3 2019.
  • 262 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2023.

Based on Azzad Asset Management's 13F filing for Q3 2023, filed 1 Apr 2024.